Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study

Abstract

The current study aimed to evaluate the efficacy of different DAAs regimens in the treatment of chronic hepatitis C (CHC) Egyptian patients who failed to achieve SVR after their treatment with SOF-based regimens. Methods: This was a retrospective observational multicenter study that included CHC patients that failed to achieve cure on SOF-based regimens who were re-treated using different DAAs regimen and were allocated according to national guidelines for the treatment of hepatitis C. Primary outcome was to assess the SVR12 rate among prior non-responders after retreatment with a second course of DAAs. Results: Our study included 172 patients who failed to achieve SVR after treatment with SOF-based treatment regimen [age: 51.2 AE 11.3, 58.7% men]. Included patients were retreated using SOF/DCV/RBV, SOF/ r/PAR /OMB /RBV, SOF/DCV/SIM, SOF/LDV AE RBV or SIM/SOF. SVR12 was successfully attained in 95.35% (164/172) of the included non-responders. Conclusion:The current multicenter study proved the efficacy of various DAAs regimens issued by the National Committee for Control of Viral Hepatitis for retreatment of relapsed CHC Egyptian patients.

Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example

“…With regard to first-line DAA failures, it is assumed that patients will switch to a different DAA in the second-line treatment setting. Evidence suggests that SVR12 rates in first-line failures (when second-line treatment occurs with a different DAA) remain high [ 26 ]. This is confirmed by several of the glecaprevir/pibrentasvir trials, which permitted enrolment of DAA-experienced individuals [ 22 ] and yielded SVR12 rates > 90%.…”